Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD40 | P25942 | 3/20 | 0.51 |
| ▸ | OPRD1 | P41143 | 7/20 | 0.47 |
| ▸ | OPRM1 | P35372 | 6/20 | 0.47 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.44 |
| ▸ | CHRND | Q07001 | 6/20 | 0.44 |
| ▸ | CHRNA1 | P02708 | 2/20 | 0.44 |
| ▸ | CHRNG | P07510 | 2/20 | 0.44 |
| ▸ | CHRNB1 | P11230 | 2/20 | 0.44 |
| ▸ | TERT | O14746 | 1/20 | 0.43 |
| ▸ | GRIA1 | P42261 | 3/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2183041 | 0.90 | NPY4R (0.43) | CHRND | |
| SCHEMBL2189511 | 0.90 | NPY4R (0.53) | CD40 | |
| SCHEMBL2192467 | 0.88 | CD40 (0.46) | CD40OPRD1OPRM1OPRK1CHRND | |
| SCHEMBL4672644 | 0.82 | MMP2 (0.48) | CHRNDCHRNA1CHRNGCHRNB1 | |
| SCHEMBL4672649 | 0.82 | MMP2 (0.48) | CHRNDCHRNA1CHRNGCHRNB1 | |
| SCHEMBL2193850 | 0.81 | NPY4R (0.58) | — | |
| SCHEMBL9333689 | 0.80 | CD40 (0.53) | CD40OPRD1OPRM1OPRK1CHRND | |
| SCHEMBL16468664 | 0.80 | NPY4R (0.52) | CHRNDCHRNA1CHRNGCHRNB1 | |
| SCHEMBL31415945 | 0.79 | CD40 (0.52) | CD40OPRD1OPRM1OPRK1 | |
| SCHEMBL23362938 | 0.79 | NPY4R (0.56) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110166063-A1 | POLYMER CONJUGATES OF THERAPEUTIC PEPTIDES | NEKTAR THERAPEUTICS (US) | 2011-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166063-A1 | POLYMER CONJUGATES OF THERAPEUTIC PEPTIDES | NGLY1, CD44, IAPP | CD40 33/4885OPRD1 3100/4885OPRM1 2317/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.